3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Chronic Phase Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Phase Chronic Myeloid Leukemia trials Research Report on Chronic Phase Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Completed | Bristol-Myers Squibb | 84 | 2014-01-22 | 2022-11-03 |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 4 | 2013-08-01 | 2020-11-02 |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Imatinib, Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Completed | Bristol-Myers Squibb | 262 | 2012-09-12 | 2023-06-22 |
Leukemia, Myeloid, Chronic-Phase (3) · Blast Crisis (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1)
Dasatinib (2) · Imatinib Mesylate (1) · nilotinib (1) · ruxolitinib (1)
Bristol-Myers Squibb (2) · University Health Network, Toronto (1)
Canada (3) · France (2) · Italy (2) · Spain (2) · United States (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Czechia (1) · Germany (1) · Hungary (1) · Poland (1) · South Korea (1)